Navigation Links
Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
Date:4/15/2011

ction of the BLA by the end of this year, which will complete the application. If approved, metreleptin would be the first therapy indicated specifically for the treatment of diabetes and high triglycerides in patients with lipodystrophy, and the first approved therapeutic use of metreleptin.

About Amylin Pharmaceuticals, Inc.

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

This press release contains forward-looking statements about Amylin which involve risks and uncertainties.  The actual results for Amylin could differ materially from those discussed due to a number of risks and uncertainties, including that the CMC section of the metreleptin BLA mentioned in this press release may not be submitted in a timely fashion, the estimate of the number of lipodystrophy patients mentioned in this press release may not be accurate, clinical trials or studies may not start when planned, confirm previous results, be predictive of real world use or achieve intended clinical endpoints; preclinical studies may not be predictive; our product candidates, including the product candidate mentioned in this press release, may not receive regulatory approval; and inherent scientific, regulatory and other risks in the drug development and commercialization process. These and additional risks and uncertainties are described more fully in Amyli
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... 2015  A technique to increase the flow of blood ... blood pressure and red blood cell levels in preterm infants ... the National Institutes of Health. The study, published ... Research Institute at Sharp Mary Birch Hospital for Women and ... Linda University, Loma Linda, California . It ...
(Date:6/29/2015)... , June 29, 2015  Relmada Therapeutics, Inc. ... for the treatment of chronic pain, announced today ... with novel formulations of oral, enteric-coated buprenorphine (collectively ... pain and opioid dependence indications has reached the ... anticipates reporting top-line results in the second half ...
(Date:6/29/2015)... BANGALORE and MOSCOW ... ReadSense, a genomics company at nanocenter TECHNOSPARK (Troitsk), ... the implementation of bioinformatics in personalized medicine, have ... Strand and ReadSense will jointly develop affordable tests ... of genetic pathologies such as hereditary forms of ...
Breaking Medicine Technology:Umbilical cord 'milking' improves blood flow in preterm infants 2Umbilical cord 'milking' improves blood flow in preterm infants 3Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark 2Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark 3The Genomic Center of Nanocenters 'Technospark' and 'Dubna', Russia and Strand Life Sciences, India to Co-develop Tests for Diagnosis of Inherited Diseases 2The Genomic Center of Nanocenters 'Technospark' and 'Dubna', Russia and Strand Life Sciences, India to Co-develop Tests for Diagnosis of Inherited Diseases 3
... 2011 Four hospitals serving Virginia patients reduced healthcare-acquired ... days, resulting in savings of $1.2 million in additional ... persistent action plan to existing federal hand washing protocols, ... fewer infections and reduced patient length-of-stay and unnecessary readmissions. ...
... Pharmaceuticals, Inc., a publicly held corporation, (Symbol: PDRX.PK) ... an electronic medical record, from Wilson Medical Software, ... quality, low-cost tool for physicians to maintain patient ... and assistants to rapidly record visit notes and ...
Cached Medicine Technology:Virginia Hospitals Reduce Infections 41% 2Virginia Hospitals Reduce Infections 41% 3PD-Rx Pharmaceuticals Acquires Wilson Medical's EMR 2
(Date:6/29/2015)... ... June 29, 2015 , ... Bionops Laboratories has released the ... French consumers. , The specialized eye health formulation contains a variety of ingredients ... In addition to Citicoline (Cognizin®), Biomacula provides necessary doses of Vitamin E, Glutathione, ...
(Date:6/29/2015)... ... 29, 2015 , ... Celebrities have many skincare secrets, and skin expert, Holly ... long and beyond. People don’t have to be famous to have fabulous skin. ... an even skin tone, avoid breakouts, and take skin health and wellness to a ...
(Date:6/29/2015)... ... June 29, 2015 , ... Blue ... two leaders with the Commercial Markets division, which includes the company’s commercial health ... Minnesota-headquartered companies with regional, national and international reach. Mary Ellen Anderson now holds ...
(Date:6/29/2015)... ... June 29, 2015 , ... Minneapolis ... the Twin Cities area, provides money-saving tactics during a season of increased water ... residents, addressing water conservation and other economical practices. , According to the ...
(Date:6/29/2015)... ... June 29, 2015 , ... National ... responsible and legal access to Health Canada's medical cannabis program, today officially opened ... on how Health Canada's medical marijuana system works. Members are connected with a ...
Breaking Medicine News(10 mins):Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 2Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 3Health News:Skin Guru Shares Celebrity FACE Secrets For Summer-Proofing The Skin 2Health News:Skin Guru Shares Celebrity FACE Secrets For Summer-Proofing The Skin 3Health News:Blue Cross and Blue Shield of Minnesota announces two new leadership appointments within its Commercial Markets division 2Health News:Blue Cross and Blue Shield of Minnesota announces two new leadership appointments within its Commercial Markets division 3Health News:Save Energy: MSP Plumbing, Heating & Air Endorses Efficiency 2Health News:Save Energy: MSP Plumbing, Heating & Air Endorses Efficiency 3Health News:National Access Cannabis Opens Flagship Ottawa Care Centre 2Health News:National Access Cannabis Opens Flagship Ottawa Care Centre 3
... In ... Dr. Abdul Rao , Chief Executive Officer and Chief Research Officer, the Institute ... cross-enterprise electronic platform for timely integration of patient-specific healthcare information. , ... (Vocus) December 14, 2009 -- In ...
... than white women to receive radiation therapy after a lumpectomy, ... to a new study by researchers at The University of ... its kind and the first to examine such racial disparities ... Cancer . It was first presented at the 2008 American ...
... technology could lead to quicker detection and treatment, study ... "nanosensors" can detect early signs of cancer in everyday ... sensors hunted for and picked up biomarkers for prostate ... of the Yale Institute for Nanoscience and Quantum Engineering ...
... SAN ANTONIO - In a large review of breast ... of Texas M. D. Anderson Cancer Center have identified ... long-associated with a favorable prognosis and multiple tumors undetected ... at the CTRC-AACR San Antonio Breast Cancer Symposium, is ...
... ... Treatment Program , ... (PRWEB) December 12, 2009 -- Eighteen year addiction ends at Narconon California Drug Treatment ... prescription drugs for the last eighteen years! Imagine finding that out just before Christmas. ...
... , MEXICO CITY, Dec. 11 Genomma Lab ... its,2010 earnings guidance. , Genomma Lab expects net ... of 2010, excluding possible acquisitions, and an EBITDA margin,between 25.0% and 26.0%, ... guidance. , The Company,s estimates are based on ...
Cached Medicine News:Health News:IWHNA CEO Abdul Rao Encourages the Use of Google Health for Establishing a Patient-Specific Comprehensive Digital Health Record Across Enterprises 2Health News:IWHNA CEO Abdul Rao Encourages the Use of Google Health for Establishing a Patient-Specific Comprehensive Digital Health Record Across Enterprises 3Health News:IWHNA CEO Abdul Rao Encourages the Use of Google Health for Establishing a Patient-Specific Comprehensive Digital Health Record Across Enterprises 4Health News:Study finds racial disparities exist in radiation therapy rates for early stage breast cancer 2Health News:Study finds racial disparities exist in radiation therapy rates for early stage breast cancer 3Health News:'Nanosensors' Spot Early Signs of Cancer 2Health News:M. D. Anderson study questions true favorability of rare breast cancer type 2Health News:Nurse Celebrates Son's Drug Addiction Recovery During Holidays 2
The SonoSite MicroMaxx gives you big machine performance in a lightweight package. This laptop-sized, durable unit represents the technology crossover point between hand-carried ultrasound and larger...
... simple and flexible solution. The Coag-A-Mate ... design, but offers full automation and ... high-volume systems. It is an easy ... also be used as a back-up ...
... KeraCel Ophthalmic Products are ... formulation of lint-free MEROCEL polyvinyl ... configured to be beneficial to ... being absorbent, and yet firm ...
... a highly sharpened surgical blade that swings across ... produced is carefully controlled to a depth that ... located, but through the rich capillary bed. The ... significantly less pain and trauma to a babys ...
Medicine Products: